Literature DB >> 35857245

A retrospective review of pregnant patients critically ill with COVID-19 in a tertiary referral centre.

Maha Al Mandhari1, Onion G Ubaldo1, Laveena Munshi1,2, Anand Lakhani3, Wendy Whittle3, Stephen E Lapinsky4,5.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35857245      PMCID: PMC9298164          DOI: 10.1007/s12630-022-02292-3

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   6.713


× No keyword cloud information.
To the Editor, COVID-19 appears to be more severe during pregnancy.[ We conducted a retrospective case review of 21 pregnant persons infected with SARS-CoV-2 admitted to the intensive care unit (ICU) at Mount Sinai Hospital (Toronto, ON, Canada) between March 2020 and June 2021 (Electronic Supplementary Material [ESM] eFig. 1). We recorded demographic and obstetric course, outcome, and data on mechanical ventilation. Positive end-expiratory pressure (PEEP) level, peak pressure, and plateau pressure were recorded using the highest three-hour average in the first 48 hr to avoid outlier measurements. We assessed compliance with the usual guidelines for prone positioning.[ Lung compliance is challenging to assess retrospectively and was not recorded. The demographics are summarized in the Table. Eleven patients required invasive mechanical ventilation, and ten were managed with oxygen therapy (including high flow nasal oxygen). Table also documents pharmacotherapy and ventilation parameters. More than half (55%) underwent prone positioning (including after Cesarean delivery) without complications. Of the five ventilated patients not proned, one met proning criteria retrospectively. Obstetrical care involved a daily assessment and communication with the ICU team. Fetal heart rate was assessed daily and a 20-min non-stress test was conducted in patients greater than 26 weeks gestation. Obstetrical ultrasound was performed on admission, once weekly, and if the maternal status deteriorated. Demographics, management, and delivery of pregnant COVID-19 patients 1Highest 3-hr mean in first 48 hr of ventilation BMI = body mass index (initial BMI on admission); ECLS = extracorporeal life support; ICU = intensive care unit; P/F = ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; PBW = predicted body weight; PEEP = positive end-expiratory pressure; SD = standard deviation Our institutional approach was to treat pregnant patients in a similar way to non-pregnant patients, and to follow usual obstetric indications for delivery (ESM eFig. 2). For corticosteroid treatment, methylprednisolone (which does not cross the placenta) was administered at 32 mg/day. If gestation was less than 34 weeks, steroid treatment in the initial 48 hr served the dual purpose of promoting fetal lung maturity and treating COVID-19; for this, dexamethasone 6 mg was administered twice daily.[ All patients received a single dose of tocilizumab, except one patient who had elevated liver enzymes. Six patients required delivery during their critical illness (Table). All deliveries were for obstetrical indications, and delivery was not performed to improve maternal respiratory status. Two patients were intubated for respiratory failure in the operating room prior to an emergent Cesarean delivery for abnormal fetal heart rate pattern. Two patients delivered in the ICU because they were too unstable for transfer to the Labor and Delivery Unit. Standard ICU sedation and analgesia (propofol and fentanyl) were continued under the supervision of obstetric anesthesia. Improvement in oxygenation post-delivery cannot be expected in all patients (ESM eFig. 3), and delivery may potentially confer adverse effects (e.g., pulmonary edema, right ventricular overload) related to the increase in central blood volume. Fifteen patients (76%) delivered after the phase of critical illness, 14 after being discharged home. Two patients with diamniotic dichorionic twin gestations experienced intrauterine fetal demise of one twin, diagnosed during critical illness. No maternal mortality occurred. Morbidity included hypoxic brain injury (one patient) and renal dysfunction requiring prolonged (but temporary) dialysis (one patient). Five out of 11 ventilated patients (45%) developed ventilator-associated pneumonia, with Staphylococcus aureus or Haemophilus influenza. Nine patients (43%) required vasopressor therapy with norepinephrine. Computed tomography angiography was performed in four patients and ultrasound leg assessment in seven patients, with two diagnosed with pulmonary embolism. This COVID-19 experience contrasts with our experience during the influenza H1N1 pandemic in 2009, when three of 12 hospitalized patients required ICU care, nine of 12 being discharged home undelivered.[ There are limited data to guide the management of respiratory failure in pregnancy. We used standard ICU management protocols and routine obstetric criteria for fetal monitoring and delivery, with excellent interdisciplinary communication between ICU, obstetrics, obstetric anesthesia, and obstetric medicine. We provided noninjurious pressure-limited ventilation, allowing permissive hypercapnia with PEEP based on best oxygenation. Transpulmonary pressure was not measured, although this may be useful in this population. Delivery was not performed as a tool to improve maternal respiratory status despite significant hypoxemia in some patients, based on our previous data,[ and all births were driven exclusively by obstetrical indications. Below is the link to the electronic supplementary material. Supplementary file1 (PDF 199 kb)
Table

Demographics, management, and delivery of pregnant COVID-19 patients

Total (N = 21)Ventilated (N = 11)Not ventilated (N = 10)
Age 18–35 years1789
Age > 35 years431
Gestation at admission (mean ± SD) weeks27.9 ± (1.0)28.3 ± (5.6)27.6 ± (4.0)
BMI (mean ± SD)33.7 (± 10.7)33.4 (± 3.8)34.7 (± 6.2)
Length of stay (days)
  ICU – days, median (range)9 (2–47)13 (4–47)3.5 (2–14)
  Hospital – days, median (range)17 (5–67)24 (8–67)10.5 (5–25)
Pharmacotherapy (n = 21)
Corticosteroids for COVID-19, n (%)20 (95%)
Remdesivir, n (%)5 (24%)
Tocilizumab, n (%)15 (76%)
Mechanical ventilation (n = 11)
Admission P/F ratio, median (range)112 (76–291)
Highest PaCO2, median (range) (mm Hg)55 (44–87)
Peak pressure1, median (range) (cm H2O)32 (23–41)
Driving pressure1, median (range) (cm H2O)17 (10–24)
PEEP1, median (range) (cm H2O)16 (12–20)
Tidal volume (ml/kg PBW)1, median (range)
  1st 24 hr6.5 (4.4–9.1)
  2nd 24 hr6.2 (4.2–10.7)
Neuromuscular blockade11 (100%)
Inhaled Nitric oxide (NO)5 (45%)
Prone positioning6 (55%)
High-frequency oscillation, ECLS, tracheostomy1 each
Duration of invasive ventilation, median (range) days10 (447)
Delivery (n = 6)
Deliveries during ICU care6 (29%)51
Primary indication
  Non-reassuring fetal status440
  Spontaneous labor101
  Intrauterine fetal demise110
Location
  Labor & delivery unit431
  ICU220
Mode of delivery
  Cesarean delivery541
  Vaginal delivery110
Mean gestational age at delivery, weeks (range)
  Delivery during ICU (liveborn)34.2 (28.8–37.8)
  Delivery after ICU stay38.1 (32.7–40.9)
Timing, median (range) days
  Intubation to delivery1 (0–20)
  Delivery to extubation5 (1–19)

1Highest 3-hr mean in first 48 hr of ventilation

BMI = body mass index (initial BMI on admission); ECLS = extracorporeal life support; ICU = intensive care unit; P/F = ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; PBW = predicted body weight; PEEP = positive end-expiratory pressure; SD = standard deviation

  5 in total

1.  Prone positioning in severe acute respiratory distress syndrome.

Authors:  Claude Guérin; Jean Reignier; Jean-Christophe Richard; Pascal Beuret; Arnaud Gacouin; Thierry Boulain; Emmanuelle Mercier; Michel Badet; Alain Mercat; Olivier Baudin; Marc Clavel; Delphine Chatellier; Samir Jaber; Sylvène Rosselli; Jordi Mancebo; Michel Sirodot; Gilles Hilbert; Christian Bengler; Jack Richecoeur; Marc Gainnier; Frédérique Bayle; Gael Bourdin; Véronique Leray; Raphaele Girard; Loredana Baboi; Louis Ayzac
Journal:  N Engl J Med       Date:  2013-05-20       Impact factor: 91.245

2.  H1N1 in pregnancy: a tertiary care centre experience.

Authors:  Ann Kinga Malinowski; Allison McGeer; Julie Robertson; Mathew Sermer; Dan Farine; Stephen E Lapinsky; Cynthia Maxwell
Journal:  J Obstet Gynaecol Can       Date:  2011-07

3.  Mechanical ventilation in critically-ill pregnant women: a case series.

Authors:  S E Lapinsky; J A Rojas-Suarez; T M Crozier; D N Vasquez; N Barrett; K Austin; G A Plotnikow; K Orellano; G Bourjeily
Journal:  Int J Obstet Anesth       Date:  2015-07-02       Impact factor: 2.603

4.  Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study.

Authors:  José Villar; Shabina Ariff; Robert B Gunier; Ramachandran Thiruvengadam; Stephen Rauch; Alexey Kholin; Paola Roggero; Federico Prefumo; Marynéa Silva do Vale; Jorge Arturo Cardona-Perez; Nerea Maiz; Irene Cetin; Valeria Savasi; Philippe Deruelle; Sarah Rae Easter; Joanna Sichitiu; Constanza P Soto Conti; Ernawati Ernawati; Mohak Mhatre; Jagjit Singh Teji; Becky Liu; Carola Capelli; Manuela Oberto; Laura Salazar; Michael G Gravett; Paolo Ivo Cavoretto; Vincent Bizor Nachinab; Hadiza Galadanci; Daniel Oros; Adejumoke Idowu Ayede; Loïc Sentilhes; Babagana Bako; Mónica Savorani; Hellas Cena; Perla K García-May; Saturday Etuk; Roberto Casale; Sherief Abd-Elsalam; Satoru Ikenoue; Muhammad Baffah Aminu; Carmen Vecciarelli; Eduardo A Duro; Mustapha Ado Usman; Yetunde John-Akinola; Ricardo Nieto; Enrico Ferrazi; Zulfiqar A Bhutta; Ana Langer; Stephen H Kennedy; Aris T Papageorghiou
Journal:  JAMA Pediatr       Date:  2021-08-01       Impact factor: 16.193

Review 5.  Pregnancy and COVID-19: pharmacologic considerations.

Authors:  R D'Souza; R Ashraf; H Rowe; J Zipursky; L Clarfield; C Maxwell; C Arzola; S Lapinsky; K Paquette; S Murthy; M P Cheng; I Malhamé
Journal:  Ultrasound Obstet Gynecol       Date:  2021-02       Impact factor: 8.678

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.